Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
Aptose Biosciences (NASDAQ: APTO) announced its participation in Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference. William G. Rice, Ph.D., Chairman and CEO, will discuss innovative treatments for acute myeloid leukemia (AML) on April 14, 2022, from 1:30 to 2:30 PM ET. The event, moderated by John Newman, will feature a panel titled 'Attacking AML: New Approaches.' The audio webcast can be accessed via Aptose's website. The company focuses on developing precision therapies for hematologic malignancies, with ongoing Phase 1 trials for its investigational products.
- None.
- None.
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias (AML) at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference:
| Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference | ||
| • | Panel: Attacking AML: New Approaches | |
| Date: | Thursday, April 14, 2022 | |
| Time: | 1:30 – 2:30 PM ET | |
| Format: | Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst | |
| Webcast: | Link | |
The audio webcast also will be accessible through the Aptose website at www.aptose.com and will be archived shortly after the live events.
The Aptose management team will be hosting 1x1 investor meetings during the event.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.
| For further information, please contact: | |
| Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com | LifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com |
FAQ
What is Aptose Biosciences discussing at the Canaccord Genuity conference on April 14, 2022?
Who will represent Aptose Biosciences at the Canaccord conference?
What is the date and time of the panel discussion on AML?
How can investors access the webcast for the Aptose panel?
What are the current clinical trials Aptose Biosciences is conducting?
